RO-0282425
| Clinical data | |
|---|---|
| Other names | RO0282425 |
| Routes of administration | Unspecified[1] |
| Drug class | Melanocortin MC4 receptor agonist |
| ATC code |
|
RO-0282425 is a melanocortin MC4 receptor agonist which was under development for the treatment of erectile dysfunction but was never marketed.[1][2] Its route of administration was unspecified.[1] The drug was under development by Roche.[1][2] It reached phase 2 clinical trials by 2005 but its development was subsequently discontinued.[1][2] The chemical structure of RO-0282425, and whether it is a small molecule or a peptide, do not appear to have been disclosed.[1]
See also
[edit]References
[edit] | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information. |